Please login to the form below

Not currently logged in
Email:
Password:

cancer patients

This page shows the latest cancer patients news and features for those working in and with pharma, biotech and healthcare.

AZ and CRUK launch Cambridge genomics centre

AZ and CRUK launch Cambridge genomics centre

identify new biological pathways driving disease and will accelerate the development of new cancer medicines for patients.”. ... We hope that this will translate into urgently needed new therapies for patients with hard to treat cancers such as lung,

Latest news

  • Genomics England reaches 100,000th genome sequencing milestone Genomics England reaches 100,000th genome sequencing milestone

    Due to the personalised nature of genome sequencing, one in four patients with a rare disease received a diagnosis for the very first time. ... Meanwhile for cancer patients, the project provided actionable findings for up to 50% of participants,

  • GSK buys cancer firm Tesaro for $5.1bn GSK buys cancer firm Tesaro for $5.1bn

    Zejula is approved in the US and Europe for recurrent ovarian cancer patients in response to platinum-based chemotherapy, with and without BRCA mutations, and made $63m in sales in the ... GSK’s head of R&D Hal Barron said that PARP inhibitors are

  • Grail to initiate largest ever UK cancer screening study Grail to initiate largest ever UK cancer screening study

    Remarkably, these cfNAs could potentially be detected before the manifestation of cancer symptoms. ... If lung cancer was diagnosed at the earliest stage, 70% of all lung cancer patients will survive for at least a year, compared to around 14% of those

  • NHS says Humira biosimilar deal will save £300m NHS says Humira biosimilar deal will save £300m

    for 11, 700 more community nurses or 19, 800 more breast cancer treatments for patients.”. ... The biosimilars should be available to patients in December, and Humira may continue to be used “where clinically appropriate or where it is the best value.

  • NICE lung cancer backing for Keytruda is biggest expansion yet NICE lung cancer backing for Keytruda is biggest expansion yet

    cell lung cancer (NSCLC) patients in combination with chemotherapy for up to two years. ... Lung cancer is the biggest cancer killer in the UK so it’s vital that innovations like this reach patients as quickly as possible.”.

More from news
Approximately 0 fully matching, plus 920 partially matching documents found.

Latest Intelligence

  • Lonely planet: why there is dwindling value in pharma travelling alone Lonely planet: why there is dwindling value in pharma travelling alone

    value over time, unlocking better outcomes for patients, health systems and society as a whole.”. ... They’re looking at the broader value that they can deliver for patients beyond the medicine.”.

  • Cancer care – the power of new technologies Cancer care – the power of new technologies

    With the number of cancer patients on the rise, we need to tackle this disparity by collaborating with the NHS and embracing the power of new technologies. ... on the tumour type that they had, with brain cancer patients highlighting a significantly

  • The future of medicine has to be data-driven The future of medicine has to be data-driven

    How combining AI and expert knowledge is supporting clinicians in the age-old battle against cancer. " />. ... By assembling these data sources, we are entering a new era where we will be able to cluster patients’ cancer cases in virtual cohorts and

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    Opdivo after standard treatment of early-stage lung cancer can reduce recurrences and help patients live longer by killing tumour cells remaining after surgery and standard chemotherapy. ... To sum up, because of the ageing and growing population, there

  • Communication is the key to unlocking the potential of immuno-oncology Communication is the key to unlocking the potential of immuno-oncology

    IO is fast becoming a lifeline to thousands of cancer patients, and has reformed our expectations and hopes for what’s possible in treating cancer. ... And for patients, the practicalities of their cancer treatment have changed.

More from intelligence
Approximately 0 fully matching, plus 44 partially matching documents found.

Latest appointments

  • BMS appoints new commercial leader, Davies joins Eisai and more BMS appoints new commercial leader, Davies joins Eisai and more

    Apeiron expands board. Cancer Immunotherapy company Apeiron has expanded its board, appointing Anderson Gaweco as its chief medical and scientific officer. ... class new treatments for cancer patients and to help transform the company into a world-class

  • Sue Mahony to retire as president of Lilly Oncology Sue Mahony to retire as president of Lilly Oncology

    We make medicines that help patients with cancer live longer and what a privilege it’s been to wake up each morning with that as my life’s work.”.

  • José Baselga joins BMS’ board of directors José Baselga joins BMS’ board of directors

    Dr Baselga is currently the physician in chief at Memorial Sloan Kettering Cancer Center, where he is responsible for the management of patients care, enhancing and expanding programmes in clinical and ... targeted cancer therapies and treating patients.

  • Taiho Oncology names Timothy Whitten as president Taiho Oncology names Timothy Whitten as president

    to focus on patients with cancer through the development of our robust pipeline and product commercialisation.”. ... I look forward to working with my colleagues at Taiho to ensure that patients continue to benefit from our products now and in the

  • BMS’ Dr Mike Burgees joins Turnstone Biologics BMS’ Dr Mike Burgees joins Turnstone Biologics

    He said: “ Turnstone Biologics is uniquely positioned to deliver breakthrough viral-based immunotherapies for patients with cancer. ... I look forward to working closely with Turnstone’s experienced team and founders, who are driven by science and

More from appointments
Approximately 0 fully matching, plus 30 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 53 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics